组织肥大细胞计数可能与胃肠道急性GVHD严重程度降低及非复发死亡率下降相关
本研究对56例接受异基因造血细胞移植(alloHCT)并在治疗前行胃肠道活检的患者进行分析,其中35例确诊胃肠道GVHD,21例活检未证实GVHD,另9例新诊断炎症性肠病作为对照。结果发现GVHD患者与无GVHD患者的肥大细胞中位数相似,但肥大细胞计数越低与胃肠道GVHD最高临床分期越高相关,每减少10个肥大细胞与1年内非复发死亡率升高相关(HR 0.77,95%CI 0.59-1.00,P=0.05)。所有alloHCT受者肥大细胞均显著少于炎症性肠病患者,接受清髓性预处理者肥大细胞中位数也显著低于减低强度预处理者。
要点
- 胃肠道GVHD分期越高,肥大细胞计数越低(1期80、2期69、3期54、4期26,P=0.01)。
- 每减少10个肥大细胞与1年内非复发死亡率升高相关(HR 0.77,95%CI 0.59-1.00,P=0.05)。
- 全部alloHCT受者肥大细胞均减少,清髓性预处理者低于减低强度预处理者(61.5 vs 78,P=0.02)。
核心结论
- 胃肠道肥大细胞在全部alloHCT患者中减少,在清髓性预处理及严重胃肠道GVHD患者中减少更明显。
- 作者认为这些新发现值得进一步研究肥大细胞在胃肠道GVHD中的生物学效应。
研究设计与样本
- 研究纳入56例接受alloHCT并在任何治疗(包括类固醇)前因诊断胃肠道GVHD行活检的患者:35例确诊胃肠道GVHD,21例活检未证实GVHD,另9例新诊断炎症性肠病作为对照。
- 肥大细胞计数为40倍放大下3个选定区域CD117+细胞计数的均值。
主要发现
- GVHD患者与无GVHD患者的肥大细胞中位数相似(59 vs 60)。
- 肥大细胞中位数与胃肠道GVHD最高临床分期显著相关:1期80、2期69、3期54、4期26(P=0.01)。
- 每减少10个肥大细胞与1年内非复发死亡率升高相关(HR 0.77,95%CI 0.59-1.00,P=0.05)。
- 全部alloHCT受者(包括无GVHD者)肥大细胞显著少于炎症性肠病患者(中位数59 vs 119,P<0.01)。
- 全部研究人群中,接受清髓性预处理者胃肠道肥大细胞中位数显著低于接受减低强度预处理者(61.5 vs 78,P=0.02)。
局限性
- 作者指出这些新发现值得进一步研究肥大细胞在胃肠道GVHD中的生物学效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The functions of mast cells in human graft-versus-host disease (GVHD) are unknown. We studied 56 patients who had an allogeneic hematopoietic cell transplantation (alloHCT) with a biopsy for diagnosis of gastrointestinal tract (GIT) GVHD before any treatment (including steroids): 35 with GIT GVHD, 21 HCT recipients whose biopsies did not confirm GVHD, and 9 with a new diagnosis of inflammatory bowel disease (IBD) as a comparison. The median number of mast cells (mean of CD117+ cells, counted in 3 selected spots under 40× magnification) was similar between patients with GVHD (59 cells) and those without GVHD (60 cells). However, the median number of mast cells was significantly associated with maximum clinical stage of GIT GVHD; the lowest counts of mast cells were observed in the highest clinical stage of GIT GVHD (stage 1, 80; stage 2, 69; stage 3, 54; stage 4, 26; P = .01). Moreover, every decrease by 10 mast cells was associated with increased nonrelapse mortality through 1 year (hazard ratio, 0.77; 95% confidence interval, 0.59-1.00; P = .05). AlloHCT recipients all had significantly fewer mast cells, even those without GVHD compared with those with IBD (median, 59 vs 119; P < .01). The median number of GIT mast cells was also significantly lower in patients who received myeloablative conditioning (61.5 cells) than in those who received reduced intensity conditioning (78 cells) in the entire study population (P = .02). We conclude that GIT mast cells are depleted in all alloHCT patients, more prominently in those receiving myeloablative conditioning and those with severe GIT GVHD. Our novel findings warrant further investigation into the biological effects of mast cells in GIT GVHD.
引用
- Ustun C, DeFor TE, Karadag FK, et al. Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Adv. 2020. PMID: 32453837. doi:10.1182/bloodadvances.2020001793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。